Summary & Overview
CPT 96411: Add-On Intravenous Push Chemotherapy Drug
CPT code 96411 denotes an add-on chemotherapy administration using an intravenous push technique for each additional drug given during a chemotherapy encounter. Nationally, this code matters because precise coding of multi-drug chemotherapy sessions affects clinical documentation, billing clarity, and accurate capture of services for payers and Medicare. Correct use ensures each additional agent is represented on the claim and supports appropriate payment and utilization tracking.
Key payers covered in this review include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the clinical context for 96411, typical sites of service, common modifiers associated with oncology billing, and how this add-on code interacts with primary chemotherapy administration codes. The publication outlines benchmarks and payer coverage patterns where available, highlights relevant coding practice considerations, and summarizes policy updates affecting chemotherapy administration coding nationally.
The intended audience includes billing professionals, oncology practice managers, compliance officers, and policy analysts seeking a clear, national-level reference for reporting add-on intravenous push chemotherapy drugs with CPT code 96411.
Billing Code Overview
CPT code 96411 is an add-on chemotherapy administration procedure used when a provider administers an additional chemotherapy drug using an intravenous push technique. This code is reported for each additional drug administered during a chemotherapy session and is billed in addition to the primary chemotherapy administration code for the encounter.
Service Type: Chemotherapy administration, intravenous push, add-on drug
Typical Site of Service: Outpatient infusion center or hospital outpatient department, and may also be used in physician office settings where intravenous chemotherapy is delivered.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with a diagnosed malignancy (for example, metastatic colorectal cancer) receiving outpatient infusion therapy in an oncology infusion center or hospital outpatient infusion suite. The attending oncology nurse or infusion pharmacist prepares and labels multiple antineoplastic agents per the oncologist’s orders. The oncologist administers a primary chemotherapy regimen intravenous infusion and then orders an additional agent to be given via intravenous push. Each separately prepared IV push antineoplastic medication administered during the same encounter is reported with add–on code 96411 in addition to the primary chemotherapy administration code (for example, 96413 or 96415 for the primary infusion). Documentation in the medical record includes medication name, dose, route (IV push), time of administration, consent, vital signs, any immediate patient response, and verification that the drug was given as an additional separate agent. Typical workflow: order entry by oncologist → pharmacy compounding/verification → bedside verification and safety checks → IV push administration by credentialed provider → documentation and billing. Typical site of service is an outpatient infusion center, hospital outpatient department, or clinic-based infusion suite where chemotherapy is administered.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
59 | Distinct procedural service | Use when another service or procedure is performed at a distinct anatomic site or during a separate encounter and reporting it is appropriate (rare for IV push but applicable when services are distinct). |
76 | Repeat procedure by same physician | Use when the same chemotherapy IV push is repeated by the same provider during the same encounter and payer policy requires modifier for repeats. |
77 | Data not provided in input | Data not available in the input. |
78 | Unplanned return to the operating/procedure room by the same physician following initial procedure for a related procedure during the postoperative period | Use only if an unplanned procedural intervention related to chemotherapy administration requires reentry into a procedural area. |
59 | Distinct procedural service | (Duplicate entry avoided in payer claims; see first 59 entry) |
25 | Significant, separately identifiable evaluation and management service by the same physician on the same day | Use when a separate E/M visit is provided and documented on the same day as chemotherapy administration. |
26 | Professional component | Use when billing only the professional component of a service where a technical component is billed separately. |
52 | Reduced services | Use when the service is partially reduced or discontinued and payer allows reporting of reduced service. |
53 | Discontinued procedure | Use if chemotherapy administration was started but discontinued due to patient reaction or clinical change. |
59 | Distinct procedural service | (Third appearance suppressed in some payer edits) |
JW | Drug discarded/ wastage | Use with the HCPCS drug J-codes when wastage is discarded; not appended to 96411 itself but may be relevant in same claim line items. |
62 | Two surgeons | Use when two providers share responsibility for the procedure; rarely applicable to chemotherapy push but used if two physicians are co-managing and payer requires modifier. |
76 | Repeat procedure by same physician | (Duplicate noted above) |
CS | Used for sequestration adjustments | Use for reporting services paid under the Medicare sequestration adjustments when applicable. |
| Taxonomy Code | Specialty | Notes |
|---|---|---|
207RG0200X | Medical Oncology | Medical oncologists order and oversee systemic chemotherapy administration. |
207RH0000X | Hematology-Oncology | Hematologist-oncologists manage combined hematologic and oncologic chemotherapy regimens. |
363L00000X | Infusion Therapy | Infusion nurses and infusion specialists perform administration and monitoring. |
207RP1001X | Internal Medicine — Oncology | Hospital-based internists with oncology focus who manage chemotherapy treatment. |
3336C0003X | Pharmacist (Clinical Oncology) | Oncology pharmacists compound and verify chemotherapy agents and may provide pharmacologic oversight. |
Related Diagnoses
| ICD-10 Code | Description | Clinical Relevance |
|---|---|---|
C18.9 | Malignant neoplasm of colon, unspecified | Colon cancer commonly treated with multi-agent IV chemotherapy where additional IV push agents may be used. |
C50.912 | Malignant neoplasm of unspecified site of right female breast | Breast cancer regimens often include multiple agents, some given by IV push as additional drugs. |
C34.90 | Malignant neoplasm of unspecified part of left bronchus or lung | Lung cancer treatments may include combination chemotherapy administered via IV push in addition to infusions. |
C71.9 | Malignant neoplasm of brain, unspecified | Systemic chemotherapy may be part of management; additional IV agents may be administered as pushes. |
C77.9 | Secondary and unspecified malignant neoplasm of lymph nodes | Metastatic disease often requires combination systemic therapy with multiple IV push agents. |
Z51.11 | Encounter for antineoplastic chemotherapy | Common encounter code used to indicate the visit is for chemotherapy administration, applicable when 96411 is reported. |
Related CPT Codes
| CPT Code | Description | Relationship to This Procedure |
|---|---|---|
96413 | Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug | Common primary infusion code billed for the initial IV chemotherapy infusion; 96411 is reported as an add-on for each additional IV push drug given. |
96415 | Chemotherapy administration, intravenous infusion technique; each additional hour (list separately in addition to code for primary infusion) | Used when the primary infusion extends beyond the initial hour; 96411 remains reportable for additional IV push agents administered. |
96372 | Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular | May be used for non-IV routes of drug administration in supportive care alongside IV chemotherapy; differs in route and is not additive to 96411. |
96409 | Chemotherapy administration, intravenous, push technique, single or initial substance | When a primary agent is given by IV push as the initial chemotherapy, 96411 would be used for each additional IV push agent administered during the same encounter. |
96417 | Chemotherapy administration, each additional sequential IV push of a different drug (add-on) | Data not provided in the input. |